Antigenic mapping of enterovirus A71 from Taiwan and Southeast Asia
Copyright © 2023. Published by Elsevier B.V..
Enterovirus A71 (EV-A71) is a non-enveloped virus possessing 4 capsid proteins: VP1-VP4. The outermost capsid protein, VP1, plays roles in both antigenicity and virulence of the virus. The concept of generating other EV-A71 genotypes of reverse genetics (rg) viruses by replacing VP1 can be made possible with synthetic biotechnology, allowing us to redesign organisms, creating unavailable ones. To determine suitable vaccine candidates against EV-A71 infections, we combined synthetic biotechnology, rg-virus production and high-fidelity determinants to produce genetically stable viruses. With the use of antigenic cartography, we are able to view the antigenic distance among various points. We analyzed and generated various EV-A71 VP1 sequences from Taiwan and Southeast Asian (SEA) countries, which were then used to produce recombinant rg-viruses and the viral proteins were purified for immunization of mice and rabbits. Antisera against various EV-A71 genotypes were used in neutralization assays against various Taiwan and SEA EV-A71 genotypes. Based on neutralization data from mice and rabbit antisera, we found that antisera produced from several genotypes were able to effectively neutralize the various Taiwan and SEA EV-A71 genotypes. Additionally, comparing the antigenic maps produced from mouse, rabbit and human antisera against different EV-A71 genotypes, a difference in clustering was seen and the spacing between points also differed. Based on antigenic mapping and neutralizing activities, B4 7008-HF and C4 M79 may be good potential vaccine candidates against EV-A71.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:212 |
|---|---|
| Enthalten in: |
Antiviral research - 212(2023) vom: 22. Apr., Seite 105569 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cheng, Dayna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigenic map |
|---|
| Anmerkungen: |
Date Completed 11.04.2023 Date Revised 27.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.antiviral.2023.105569 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353286117 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353286117 | ||
| 003 | DE-627 | ||
| 005 | 20231226055639.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.antiviral.2023.105569 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM353286117 | ||
| 035 | |a (NLM)36822369 | ||
| 035 | |a (PII)S0166-3542(23)00047-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cheng, Dayna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antigenic mapping of enterovirus A71 from Taiwan and Southeast Asia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.04.2023 | ||
| 500 | |a Date Revised 27.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a Enterovirus A71 (EV-A71) is a non-enveloped virus possessing 4 capsid proteins: VP1-VP4. The outermost capsid protein, VP1, plays roles in both antigenicity and virulence of the virus. The concept of generating other EV-A71 genotypes of reverse genetics (rg) viruses by replacing VP1 can be made possible with synthetic biotechnology, allowing us to redesign organisms, creating unavailable ones. To determine suitable vaccine candidates against EV-A71 infections, we combined synthetic biotechnology, rg-virus production and high-fidelity determinants to produce genetically stable viruses. With the use of antigenic cartography, we are able to view the antigenic distance among various points. We analyzed and generated various EV-A71 VP1 sequences from Taiwan and Southeast Asian (SEA) countries, which were then used to produce recombinant rg-viruses and the viral proteins were purified for immunization of mice and rabbits. Antisera against various EV-A71 genotypes were used in neutralization assays against various Taiwan and SEA EV-A71 genotypes. Based on neutralization data from mice and rabbit antisera, we found that antisera produced from several genotypes were able to effectively neutralize the various Taiwan and SEA EV-A71 genotypes. Additionally, comparing the antigenic maps produced from mouse, rabbit and human antisera against different EV-A71 genotypes, a difference in clustering was seen and the spacing between points also differed. Based on antigenic mapping and neutralizing activities, B4 7008-HF and C4 M79 may be good potential vaccine candidates against EV-A71 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Antigenic map | |
| 650 | 4 | |a Antigenicity | |
| 650 | 4 | |a EV-A71 | |
| 650 | 4 | |a Enterovirus A71 | |
| 650 | 4 | |a VP1 | |
| 650 | 4 | |a Vaccine candidate | |
| 650 | 7 | |a Antigens, Viral |2 NLM | |
| 650 | 7 | |a Capsid Proteins |2 NLM | |
| 700 | 1 | |a Huang, Sheng-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Yi-Hsuan |e verfasserin |4 aut | |
| 700 | 1 | |a Lien, Yun-Yin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jen-Ren |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antiviral research |d 1983 |g 212(2023) vom: 22. Apr., Seite 105569 |w (DE-627)NLM012601756 |x 1872-9096 |7 nnns |
| 773 | 1 | 8 | |g volume:212 |g year:2023 |g day:22 |g month:04 |g pages:105569 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.antiviral.2023.105569 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 212 |j 2023 |b 22 |c 04 |h 105569 | ||